Cradle cap
Methodology & AI Transparency ⓘ
Cradle cap Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cataloged under federal diagnostic code L21.0 in Skin & Dermatology, Cradle cap requires topical retinoids/calcineurin/steroid sparing in Cradle cap (L21.0: regimens) so specialists can calibrate treatment intensity against Fasting Lipids & in Cradle cap (L21.0: ALT (if systemic) benchmarks.
- 2 Real-world patient consensus: Diagnostic registry L21.0: Cradle cap is managed within Skin & Dermatology.
- 3 Typical cash cost range: Differential triage of Cradle cap (L21.0) utilizes topical retinoids/calcineurin/steroid sparing in Cradle cap (L21.0: regimens).
- 4 Top reported side effects / signs: Follow-up benchmark in Cradle cap: maintaining Fasting Lipids & in Cradle cap (L21.0: ALT (if systemic) within Within baseline reference limits (L21.0).
Ask our AI Specialists anything about Cradle cap
What Is Cradle cap?
Cataloged under federal diagnostic code L21.0 in Skin & Dermatology, Cradle cap requires topical retinoids/calcineurin/steroid sparing in Cradle cap (L21.0: regimens) so specialists can calibrate treatment intensity against Fasting Lipids & in Cradle cap (L21.0: ALT (if systemic) benchmarks.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Cradle cap (L21.0) features cutaneous immune skewing in Cradle cap (L21.0: (Th2/IL-4/IL-13 in atopic). therapeutic stabilization in skin & dermatology is verified against 25-Hydroxy Vitamin D in Cradle cap (L21.0: & hs-CRP).
Common Symptoms & Clinical Signs
- • Presentation of Cradle cap (L21.0): compromised epidermal barrier in Cradle cap (L21.0: with dryness, fissuring,)
- • Secondary Cradle cap clinical sign: post-inflammatory hyperpigmentation, facial in Cradle cap (L21.0: flushing, or pitted)
- • Symptom flares in Cradle cap correlating with Fasting Lipids & in Cradle cap (L21.0: ALT (if systemic) deviation outside Within baseline reference limits (L21.0)
- • Functional skin & dermatology impact requiring topical retinoids/calcineurin/steroid sparing in Cradle cap (L21.0: regimens) evaluation (L21.0)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Cradle cap Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L21.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Fasting Lipids & in Cradle cap (L21.0: ALT (if systemic) | Within baseline reference limits (L21.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Cradle cap (L21.0: & hs-CRP) | 25(OH)D 40–65 ng/mL (L21.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Affected Body Surface in Cradle cap (L21.0: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (L21.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Cradle cap
Treatment selection for Cradle cap depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Cradle cap)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Tazarotene 0.045% Lotion for Moderate-to-Severe Acne Patients: Pooled Phase 3: What a 1,013-Participant Study Found Tazarotene 0.045% lotion is efficacious and well tolerated in female and male adolescents and adults with moderate-to-severe acne. Journal of drugs in dermatology : JDD • 2021-06-01 • Phase III Randomized Trial | N = 1,013 | 90/100 | PMID 34076400 ↗ |
| Can This Approach Help? Inside the Latest Research on Dupilumab treatment improves signs, symptoms, quality of life, and work Dupilumab single-drug treatment resulted in significant improvements across different domains of H/F AD with acceptable safety, supporting dupilumab as a systemic treatment approach for this often difficult to treat condition. Journal of the American Academy of Dermatology • 2024-06-15 • Phase III Randomized Trial | N = 133 | 88/100 | PMID 38296199 ↗ |
| What the Latest Evidence Really Says About Associations between COVID-19 and skin conditions identified through epidemiology Together our findings suggest association between inflammatory skin conditions and higher risk of COVID-19, but with less severe course, and highlight shared components involved in anti-COVID-19 immune response. The Journal of allergy and clinical immunology • 2021-03-15 • Meta-Analysis | Multi-cohort | 86/100 | PMID 33485957 ↗ |
| Managing Scalp Psoriasis: Can Guselkumab Make a Real Difference? (What New Research Reveals) Within-subject correlations were 0.83 between scalp-specific Investigator's Global Assessment and Psoriasis Area and Severity Index head scores and 0.78 between scalp-specific Investigator's Global Assessment and Psoriasis... Acta dermato-venereologica • 2024-03-04 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 38436429 ↗ |
Cradle cap Patient Community & “People Like Me” Threads
Filter Cradle cap community threads and patient logs by age, biological sex, dosage, and treatment duration.